QUESTIONS
Ipamorelin: the questions people actually ask, answered straight.
Direct, cited answers drawn from the peer-reviewed record — no hype, no dosing advice.
Is ipamorelin banned by WADA?
Yes. Ipamorelin and other growth hormone secretagogues are prohibited in sport at all times under the World Anti-Doping Agency's category S2 [7]. The ban is enforceable in practice: analysts have identified even glycine-modified designer analogues of ipamorelin in seized doping material by mass spectrometry, showing detection methods extend beyond the plain compound [7].
Can ipamorelin be detected in a drug test?
In an anti-doping test, yes. Accredited laboratories detect ipamorelin and its urinary metabolites using published methods — a direct-urine-injection technique screens it among 17 other prohibited small peptides at limits of detection of 50-500 pg/mL [9]. Because its terminal half-life is only about 2 hours [2], the drug clears quickly, but the detection window is far longer since labs target metabolites too [11].
What is ipamorelin?
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively triggers growth hormone release by activating the ghrelin / GHS-R1a receptor [1]. Its defining trait, established in 1998, is selectivity: it releases growth hormone potently without raising cortisol or prolactin even far above its active dose [1]. It is a research chemical, not an approved drug.
What does ipamorelin do for you?
In studies, ipamorelin triggers a single pulse of growth hormone by activating the ghrelin receptor, doing so selectively without spiking stress hormones [1]. Beyond that mechanism, proven human benefits are absent: its one human efficacy trial, for postoperative ileus, failed [3]. Reported effects like better sleep are anecdotal community accounts, not trial results — see the effects page.
What is ipamorelin peptide?
Ipamorelin peptide is a chain of five amino acids — sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 — engineered for resistance to enzymatic breakdown and selective activation of the ghrelin (GHS-R1a) receptor on pituitary cells [1]. It is wholly synthetic, mimicking natural ghrelin's action, with a molecular weight of about 712 daltons. It has never been approved as a drug.
What are the risks of ipamorelin?
The honest answer is that ipamorelin's biggest risk is unknown long-term safety: its only Phase 2 trial ran just seven days and missed its endpoint [3], and no long-term human data exist. A class-level concern comes from a 28-day study of a related ghrelin-receptor agonist that found heart-muscle damage in rats [6]. Mechanistic cautions also apply for cancer, diabetes, and heart disease.
Does ipamorelin reduce belly fat?
There is no human evidence that ipamorelin reduces belly fat. The relevant data are animal-only: a 2024 ferret study found ipamorelin (1-3 mg/kg) inhibited chemotherapy-induced weight loss by about 24%, a protective effect against wasting rather than fat loss [5]. Community reports of a leaner appearance are anecdotal and confounded by diet and training — not a measured fat-loss outcome.
What are the downsides of ipamorelin?
The central downside is that the marketing far outpaces the evidence: the one human efficacy trial failed [3], and most claims rest on mechanism and short animal studies. Practical reported downsides include facial flushing, water retention, and increased hunger (all anecdotal). The deeper downside is uncharacterized long-term safety, against a class-level cardiac signal in a related compound [6].
Why is ipamorelin being discontinued?
Ipamorelin was never a marketed drug to discontinue — its clinical development simply stopped after its only Phase 2 trial missed its primary endpoint for postoperative ileus (25.3 vs 32.6 hours to first tolerated meal, p=0.15) [3]. Separately, in 2024 the FDA removed ipamorelin acetate from the interim Section 503A bulk-substances list, tightening compounding-pharmacy access — which can read like a discontinuation.
What does CJC-1295 and ipamorelin do?
They raise growth hormone through two different receptors and are paired to exploit synergy: CJC-1295 mimics growth-hormone-releasing hormone while ipamorelin activates the ghrelin receptor [1]. In rats, GHRH and a GHRP given together produced growth-hormone peaks greater than the sum of each alone [12]. No controlled human trial of the combination exists for any outcome — the synergy is shown at the bench, not in people.
Does ipamorelin increase IGF-1?
Not reliably in short studies. Growth hormone normally drives the liver to make IGF-1, but a rat bone-growth study found ipamorelin raised longitudinal bone growth dose-dependently with no measurable change in total IGF-1 [4], suggesting a partly local, pulse-driven effect. Whether sustained human protocols meaningfully raise IGF-1 has not been characterized in controlled trials.
How does CJC-1295 ipamorelin work?
CJC-1295 acts on the GHRH receptor (mimicking growth-hormone-releasing hormone) while ipamorelin acts on the ghrelin / GHS-R1a receptor [1] — two distinct pathways. Blocking endogenous GHRH attenuates GHRP-induced growth-hormone release, so GHRH tone is required for full GHRP effect [13]. Combining a GHRH analog with a ghrelin-receptor agonist therefore produces a larger, synergistic growth-hormone pulse than either alone [12].
How much CJC-1295 ipamorelin should I take?
No evidence-based dose exists. No controlled human trial of the ipamorelin and CJC-1295 combination has been run for any outcome; the pairing's rationale is mechanistic synergy shown in rodents [12]. Community "stack" protocols are anecdotal, have no peer-reviewed human dosing basis, and are not a recommendation. This site does not provide a dose because no published human dosing science supports one.
Does CJC-1295 ipamorelin work?
Mechanistically the pairing makes sense — combining a GHRH analog with a ghrelin-receptor agonist produces synergistic growth-hormone release in animals, greater than the sum of each alone [12]. Whether it "works" for a human goal like fat loss or muscle gain is untested: there is no controlled human trial of the combination for any outcome. Reported results are anecdotal and confounded by diet and training.
How to reconstitute CJC-1295 ipamorelin 5mg?
Only general peptide-handling description is supported, not a clinical preparation protocol. Ipamorelin is supplied as a lyophilized (freeze-dried) powder and, as a peptide, degrades with heat and freeze-thaw, so solutions are typically kept refrigerated for laboratory handling. This site provides no human-administration instructions; the only studied human routes were intravenous and supervised [2].
How long does ipamorelin stay in your system?
Its terminal half-life in humans is about 2 hours, with the growth-hormone pulse peaking near 40 minutes after dosing [2] — so pharmacologically it clears within roughly a day. But the anti-doping detection window is longer, because labs screen for metabolites as well as the parent peptide [11], at picogram-per-milliliter sensitivity [9]. The half-life page covers both clocks in detail.
Does ipamorelin make you hungry?
It can, and the mechanism explains why: ipamorelin activates the ghrelin receptor, the same receptor that drives the body's "hunger" signal [1]. In community reports, increased appetite after injecting is occasionally reported and described as milder than with the older peptide GHRP-6 — anecdotal, not a measured trial outcome. No human study has quantified an appetite effect of ipamorelin at research-use doses.
Will I gain weight on ipamorelin?
There is no human trial answering this. Ipamorelin's only Phase 2 human study tested bowel recovery, not body weight, and failed its endpoint [3]. In animals it has shown both appetite-raising effects and, in a ferret model, protection against wasting [5]. Any weight change in community use is anecdotal and heavily confounded by diet, training, and concurrent compounds.
Does ipamorelin increase appetite?
Mechanistically, yes, it would be expected to: ipamorelin acts on the ghrelin (GHS-R1a) receptor, the body's primary appetite-driving receptor [1]. Community accounts occasionally report increased hunger after injecting, described as milder than older ghrelin-receptor peptides — but this is anecdotal experience. No controlled human study has measured an appetite change from ipamorelin at the doses used in the community.
What does ipamorelin peptide do?
Ipamorelin peptide selectively prompts the pituitary to release a pulse of growth hormone by activating the ghrelin / GHS-R1a receptor, without meaningfully raising cortisol or prolactin [1]. That selective growth-hormone release is its established action. Downstream human benefits are not proven — its one human efficacy trial failed [3] — and reported effects such as improved sleep are anecdotal community accounts.
How long does it take for ipamorelin to work?
Pharmacologically, fast: after dosing, the growth-hormone response is a single discrete pulse peaking about 40 minutes (0.67 h) later, with a roughly 2-hour terminal half-life [2]. That describes the hormonal response timing, not a human outcome benefit. Community reports of effects like improved sleep within one to two weeks are anecdotal and unverified, not measured study results.
Does ipamorelin cause water retention?
Mild water retention is occasionally reported in community accounts, typically in the first few weeks and described as milder than with older peptides — anecdotal, not a trial-measured effect. Mechanistically it is plausible: growth-hormone excess is associated with sodium and fluid retention. The only controlled human trial assessed bowel recovery, not fluid balance, and is not a source for this question [3].